- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT02532907
Study of Hepatic Responses in Patients Receiving Direct-acting Anti-HCV Drugs
This study is designed to obtain and store samples of serum and liver tissue in HCV (HepC Virus)-infected patients being treated with direct-acting antiviral (DAA) therapy, and to determine the effect of new DAA therapies on HCV-related responses in the liver and peripheral blood.
The introduction of new DAAs regimens that do not include IFN provides unique and novel opportunities to examine whether successful treatment-induced eradication of viral antigen results in reconstitution of T cell immunity. serum and liver tissue samples will be collected and stored in hopes of improving treatment and outcomes for future patients.
Studieoversikt
Detaljert beskrivelse
This study is designed to obtain and store samples of serum and liver tissue in HCV-infected patients being treated with DAA therapy.
A liver biopsy will be performed pre-treatment for research reasons. A small liver sample that is not required for pathologic analysis will also be stored. Patients will undergo another liver biopsy at either 4 or 12 weeks after initiation of DAA therapy.
Any patients with HCV-related liver disease (age > 18) will be considered for this study.
Patients will have a 120 ml blood draw for research purposes at baseline and 12 weeks after stopping DAA treatment along with a 60 ml blood draw at 2, 4, 8, and 12 weeks of treatment.
The liver biopsy at baseline and then either at 4 or 12 weeks will be examined using molecular techniques to measure transcription of key genes involved in the antiviral response.
Studietype
Registrering (Faktiske)
Kontakter og plasseringer
Studiesteder
-
-
Colorado
-
Aurora, Colorado, Forente stater, 80045
- Sandra Boimbo
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria
- Signed informed consent
- Ages 18-70
- HCV-infected patients being treated with direct-acting antiviral (DAA) therapy.
Exclusion Criteria
- Pregnant women or females of childbearing potential that are not on contraception
- Institutionalized or mentally disabled persons
- Prisoners
- Unwilling or unable to provide informed consent
- Subjects who are HIV positive
- Anticipated inability to follow up
- Chronic anemia
- Platelet count < 100 for liver biopsy patients who have documented fatty liver disease by ultrasound prior to enrollment
- Any patient with bleeding disorders or prolonged INR
- Abstinent or consuming less than two drinks of alcohol per day.
- Clinical hepatic decompensation (i.e., ascites, encephalopathy or variceal hemorrhage).
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
---|---|
Patients who will have their second Liver biopsy at week 4
The 4 week time point is performed in lieu of the 12 week and the purpose of this time point is to evaluate earlier responses and transcriptional changes that might predict viral clearance or treatment failure in a subset of patients.
|
patients will get a research liver biopsy pre-DAA treatment and either 4 or the standard 12 week time point.
The liver biopsy is performed using standard protocol with ultrasound guidance.
|
Patients who will have their second Liver biopsy at week 12
Liver biopsies will be obtained at week 12 when most DAA treatments end in order to compare the hepatic responses induced or reduced by clearance of HCV
|
patients will get a research liver biopsy pre-DAA treatment and either 4 or the standard 12 week time point.
The liver biopsy is performed using standard protocol with ultrasound guidance.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Changes in gene array from baseline to either 4 or 12 weeks after treatment.
Tidsramme: 1 year
|
To examine the effect of new DAA therapies on HCV-related responses in the liver and peripheral blood.
|
1 year
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Hugo Rosen, MD, University of Colorado, Denver
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 14-1794
- UL1TR001082 (U.S. NIH-stipend/kontrakt)
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Hepatitt C
-
Dokuz Eylul UniversityEge UniversityFullførtMMP9 | TIMP1 | MMP9 -1562 C/T | TIMP1 372 T/CTyrkia
-
Hadassah Medical OrganizationXTL BiopharmaceuticalsTilbaketrukketKronisk hepatitt C virusinfeksjonIsrael
-
Hadassah Medical OrganizationUkjentKronisk hepatitt C virusinfeksjonIsrael
-
Beni-Suef UniversityFullførtٍٍSofosbuvir/Simeprevir/Daclatasvir/Ribavirin og HCV genotype 4-infiserte egyptisk erfarne deltakereKronisk hepatitt C virusinfeksjonEgypt
-
University College CorkDupont Applied BiosciencesRekruttering
-
Trek Therapeutics, PBCFullførtKronisk hepatitt C | Hepatitt C genotype 1 | Hepatitt C (HCV) | Hepatitt C viral infeksjonForente stater, New Zealand
-
Trek Therapeutics, PBCFullførtKronisk hepatitt C | Hepatitt C (HCV) | Hepatitt C genotype 4 | Hepatitt C viral infeksjonForente stater
-
Humanity and Health Research CentreBeijing 302 HospitalFullførtKronisk hepatitt C-infeksjonKina
-
Tripep ABInovio PharmaceuticalsUkjentKronisk hepatitt C virusinfeksjonSverige
-
Meir Medical CenterFullførtUtvikle ny teknikk for å måle C/D-forhold fra digitale stereooptiske plater | Intraobserver reproduserbarhet av C/D-målinger | Interobservatørvariabilitet av C/D-målinger
Kliniske studier på Liver Biopsy
-
Cliniques universitaires Saint-Luc- Université...Université de LiègeRekrutteringCystisk fibrose | BiomarkørerBelgia
-
Atos Medical ABRoyal Brisbane and Women's Hospital; Princess Alexandra Hospital, Brisbane... og andre samarbeidspartnereFullført
-
Baylor College of MedicineFullført
-
Atos Medical ABInstituto de Cancer Dr ArnaldoHar ikke rekruttert ennå
-
Heidelberg UniversityGerman Federal Ministry of Education and Research; University of Ulm; Universitätsklinikum... og andre samarbeidspartnereFullførtTrening | FallforebyggingTyskland
-
University of Kansas Medical CenterFullført
-
University of MichiganNational Institute of Nursing Research (NINR)FullførtKronisk obstruktiv lungesykdomForente stater
-
Atos Medical ABFondazione Policlinico Universitario Agostino Gemelli IRCCSFullført
-
SK Plasma Co., Ltd.FullførtImmun trombocytopeniKorea, Republikken
-
Norwegian University of Science and TechnologyUniversity of Bologna; University of Manchester; VU University of Amsterdam; Ecole Polytechnique Fédérale de Lausanne og andre samarbeidspartnereFullførtUnge eldre voksneTyskland, Nederland, Norge